Akili Secures $160 Million In Financing; Poised To Deliver On The Promise Of Digital Therapeutics

May 26, 2021•over 4 years ago

Amount Raised

$160 Million

Boston

Description

Akili Interactive (“Akili” or “Company”), maker of EndeavorRxTM, the first and only prescription video game treatment, today announced $160M in combined equity and debt financing. Akili is a pioneer of a new class of medicine and treatments that are not only effective and clinically-validated but that deliver amazing experiences to patients. The Company’s flagship product made history in June 2020 when it received U.S. Food and Drug Administration (FDA) clearance

Company Information

Company

Akili

Location

Boston, Massachusetts, United States

About

Akili is combining scientific and clinical rigor with the ingenuity of the tech and entertainment industries to challenge the status quo of medicine. Akili is pioneering the development of digital treatments and care solutions to help people affected by cognitive impairments. Akili’s treatments are designed to directly activate the networks in the brain responsible for cognitive function and have been rigorously tested in extensive clinical studies, including prospective randomized, controlled trials. Driven by Akili’s belief that effective medicine can also be fun and engaging, Akili’s treatments are delivered through captivating action video game experiences. For more information, please visit www.akiliinteractive.com.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Akili Secures $160 Million In Financing; Poised To Deliver On The Promise Of Digital Therapeutics

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information